Install the app
How to install the app on iOS

Follow along with the video below to see how to install our site as a web app on your home screen.

Note: This feature may not be available in some browsers.


Xencor begins XmAb5871 Phase 2 trials in patients with IgG4-RD and Systemic Lupus Erythematosus

E

EGBOT

Guest
Xencor begins XmAb5871 Phase 2 trials in patients with IgG4-RD and Systemic Lupus Erythematosus

HTML:
Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced dosing the first patient in a Phase 2 trial of XmAb5871 in patients with IgG4-Related Disease (IgG4-RD).

Source: Xencor begins XmAb5871 Phase 2 trials in patients with IgG4-RD and Systemic Lupus Erythematosus
 

Create an account or login to comment

You must be a member in order to leave a comment

Create account

Create an account on our community. It's easy!

Log in

Already have an account? Log in here.

Similar threads

A recent Mayo Clinic study highlights the link between glucocorticoid dosage and outcomes in patients with lupus nephritis, a type of kidney...
Replies
0
Views
208
  • Featured
  • Article Article
At the max dose according to Drs. 2.4 mg give or take Only real side I've noticed is burps that taste like fermented best I can describe...
Replies
13
Views
842
Interested in using tirzepatide for weight loss research? Inside, we detail everything researchers must know about using tirzepatide peptide...
Replies
0
Views
412

Latest threads

Back
Top